BioCentury: Biotech leaders call on peers to lobby for IRA change

Mar 23

Written By Marshall Bursis

Marshall Bursis

BioCentury: New cost-effectiveness model aims to better capture value of medicines to society

The Well News: Misguided Rating Cancels Rare Disease Patients